Efficacy of vitamins C, E, and their combination for treatment of restless legs syndrome in hemodialysis patients: A randomized, double-blind, placebo-controlled trial

Sleep Medicine

Volumn 13, Issue 5, 2012, Pages 542-545

  Sagheb, Mohammad Mahdi ^a   Dormanesh, Banafshe ^b   Fallahzadeh, Mohammad Kazem ^c   Akbari, Hamideh ^a   Sohrabi Nazari, Sahar ^a   Heydari, Seyed Taghi ^c   Behzadi, Saeed ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidants; Ascorbic acid; Restless legs syndrome; Sleep disorders; Tocopherols; Uremia

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BENZODIAZEPINE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; OPIATE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PARALLEL DESIGN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SCORING SYSTEM;

ASCORBIC ACID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME; VITAMIN E; VITAMINS;

EID: 84859494573     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.11.010     Document Type: Article

References (26)

1. Araujo S.M., de Bruin V.M., Nepomuceno L.A., Maximo M.L., Daher Ede F., Correia Ferrer D.P., et al. Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med 2010, 11:785-790.
2. Kavanagh D., Siddiqui S., Geddes C.C. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004, 43:763-771.
3. Molnar M.Z., Novak M., Mucsi I. Management of restless legs syndrome in patients on dialysis. Drugs 2006, 66:607-624.
4. de Oliveira M.M., Conti C.F., Valbuza J.S., de Carvalho L.B., Do Prado G.F. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. Mov Disord 2010, 25:1335-1342.
5. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
6. Cikrikcioglu M.A., Hursitoglu M., Erkal H., Kinas B.E., Sztajzel J., Cakirca M., et al. Oxidative stress and autonomic nervous system functions in restless legs syndrome. Eur J Clin Invest 2011, 41:734-742.
7. Ayres S., Mihan R. Leg cramps (systremma) and "restless legs" syndrome. Response to vitamin E (tocopherol). Calif Med 1969, 111:87-91.
8. Ayres S. Treatments for restless legs syndrome. West J Med 1986, 145:522-523.
9. Khajehdehi P., Mojerlou M., Behzadi S., Rais-Jalali G.A. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001, 16:1448-1451.
10. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
11. Handelman G.J. Vitamin C neglect in hemodialysis: sailing between Scylla and Charybdis. Blood Purif 2007, 25:58-61.
12. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol 2004, 4:26.
13. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132.
14. Winkelman J.W. Considering the causes of RLS. Eur J Neurol. 2006, 13(Suppl. 3):8-14.
15. Allen R.P. Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007, 120:S13-S21.
16. Saeed S.A., Elsharkawy M., Elsaeed K., Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 2008, 12:471-479.
17. Dantoine T.F., Debord J., Charmes J.P., Merle L., Marquet P., Lachatre G., et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998, 9:2082-2088.
18. Tarng D.C. Novel aspects of vitamin C in epoetin response. J Chin Med Assoc 2007, 70:357-360.
19. Buchholz P. Renal Vitamins. J Ren Nutr 2006, 16:e1-e6.
20. Lee H.Y., Naha N., Ullah N., Jin G.Z., Kong I.K., Koh P.O., et al. Effect of the co-administration of vitamin C and vitamin E on tyrosine hydroxylase and Nurr1 expression in the prenatal rat ventral mesencephalon. J Vet Med Sci 2008, 70:791-797.
21. Seitz G., Gebhardt S., Beck J.F., Bohm W., Lode H.N., Niethammer D., et al. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH. Neurosci Lett 1998, 244:33-36.
22. Kalantar-Zadeh K., Lee G.H. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Nephrol 2006, 1(Suppl. 1):S9-S18.
23. Sloand J.A., Shelly M.A., Feigin A., Bernstein P., Monk R.D. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
24. Sun Y.M., Hoang T., Neubauer J.A., Walters A.S. Opioids protect against substantia nigra cell degeneration under conditions of iron deprivation: a mechanism of possible relevance to the restless legs syndrome (RLS) and Parkinson's disease. J Neurol Sci 2011, 304:93-101.
25. Evangelou A., Kalfakakou V., Georgakas P., Koutras V., Vezyraki P., Iliopoulou L., et al. Ascorbic acid (vitamin C) effects on withdrawal syndrome of heroin abusers. In Vivo 2000, 14:363-366.
26. Fulda S., Wetter T.C. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008, 131:902-917.